Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
نویسندگان
چکیده
BACKGROUND Alosetron is a potent and selective 5-HT3 receptor antagonist, which has been shown to be beneficial in the treatment of female patients with non-constipated irritable bowel syndrome. AIMS To investigate the effect of alosetron on whole gut, small bowel and colonic transit in patients with irritable bowel syndrome (Study 1) and healthy volunteers (Study 2). SUBJECTS Thirteen patients with irritable bowel syndrome and 12 healthy volunteers. METHODS Both studies were randomized, double-blind, placebo-controlled with a two-way crossover design, in which each subject received alosetron (2 mg b.d. administered orally) or placebo for 8 days. Mean whole gut transit was determined from the excretion of radio-opaque markers; small bowel transit was determined from rise in breath hydrogen after a meal; and colonic transit and segmental transit were evaluated from abdominal X-ray. In addition, colonic transit was calculated by subtracting small bowel transit time from whole gut transit time. RESULTS Alosetron increased colonic transit time by prolonging left colonic transit in both patients with irritable bowel syndrome and controls. This resulted in a tendency for the whole gut transit to be delayed in irritable bowel syndrome patients (P=0.128), which was confirmed in controls (P=0.047). CONCLUSION Alosetron delays colonic transit by prolonging left colonic transit. These results add to the body of evidence suggesting that alosetron should have a therapeutic role in patients with non-constipated irritable bowel syndrome.
منابع مشابه
Serotonin receptor modulation in irritable bowel syndrome: one step forwards and one step backwards.
Comment The pharmacological treatment of irritable bowel syndrome (IBS) is currently far from satisfactory and there have been no new drug developments for many years. Recently, there has been a surge of interest in serotonin and the gut with particular emphasis, where IBS is concerned, on 5-HT3 and 5-HT4 receptors. A number of agonists and antagonists of these receptors are now under investiga...
متن کاملEfficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials
AIM We assessed the efficacy and safety of 5-hydroxytryptamine (5-HT3) receptor antagonists in adults with non-constipated irritable bowel syndrome (IBS) or diarrhea-predominant IBS (IBS-D). METHODS We searched PubMed, MEDLINE, EMBASE, and the Cochrane Controlled Trials Register for randomized controlled trials (RCTs) involving adults with non-constipated IBS or IBS-D that compared 5-HT3 rece...
متن کاملNeural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study.
BACKGROUND Symptom improvement in irritable bowel syndrome (IBS) treatment trials varies widely, with only 50-70% of patients qualifying as responders. Factors predicting treatment responsiveness are not known, although we have demonstrated that symptom improvement with the 5-HT3R antagonist alosetron is correlated with reduced amygdala activity. AIM To determine whether neural activity durin...
متن کاملIrritable Bowel Syndrome: Medical and Nutritional Therapies
Table 1. Symptom – Based Treatment of Irritable Bowel Syndrome Pain Predominant Diarrhea Predominant Constipation Predominant Antispasmodic Agents Dicycloverine (Bentyl) Mebeverine Tricyclic Antidepressants Amitriptyline Antidiarrheal Agents Loperamide (Imodium) Cholestyramine (questran) Serotonin (5-HT3) antagonist Alosetron (Lotronex) Ondansetron (Zofran) Serotonin (5-HT4) Agoni...
متن کاملMedium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea.
BACKGROUND Carcinoid diarrhoea is associated with rapid small bowel and proximal colonic transit. Intravenous administration of a serotonin type 3 receptor (5HT3) antagonist restores postprandial colonic tone towards normal in carcinoid patients. AIMS To evaluate the medium-term effects of an oral 5HT3 antagonist, alosetron, on symptoms, stool fat, and transit in patients with carcinoid diarr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Alimentary pharmacology & therapeutics
دوره 14 6 شماره
صفحات -
تاریخ انتشار 2000